Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
1998 2
1999 1
2000 1
2001 4
2002 6
2003 8
2004 11
2005 8
2006 7
2007 7
2008 10
2009 10
2010 9
2011 19
2012 38
2013 36
2014 39
2015 32
2016 35
2017 25
2018 43
2019 44
2020 43
2021 48
2022 46
2023 40
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

462 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Staging of Bladder Cancer.
Ahmadi H, Duddalwar V, Daneshmand S. Ahmadi H, et al. Among authors: daneshmand s. Hematol Oncol Clin North Am. 2021 Jun;35(3):531-541. doi: 10.1016/j.hoc.2021.02.004. Epub 2021 Apr 15. Hematol Oncol Clin North Am. 2021. PMID: 33958149 Review.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S. Powles T, et al. Among authors: daneshmand s. Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Among authors: daneshmand s. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Chang SS, et al. Among authors: daneshmand s. J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. J Urol. 2016. PMID: 27317986 Review.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Bellmunt J, et al. Among authors: daneshmand s. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721560 Free PMC article. Clinical Trial.
Preface.
Daneshmand S. Daneshmand S. Urol Clin North Am. 2019 Aug;46(3):xiii. doi: 10.1016/j.ucl.2019.05.002. Urol Clin North Am. 2019. PMID: 31277740 No abstract available.
Continent Cutaneous Diversion.
Pearce SM, Daneshmand S. Pearce SM, et al. Among authors: daneshmand s. Urol Clin North Am. 2018 Feb;45(1):55-65. doi: 10.1016/j.ucl.2017.09.004. Urol Clin North Am. 2018. PMID: 29169451 Review.
462 results